Otezla — Finite-lived intangible assets, fair value disclosure
Products & Services · Finite-lived intangible assets, fair value disclosureAmgen Otezla — Finite-lived intangible assets, fair value disclosure decreased by 25.0% to $3.00B in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryCapital Allocation
SignalHigher is better
VolatilityStable
First reportedQ1 2025
Last reportedQ4 2025
How to read this metric
An increase suggests rising valuation of the product's intellectual property, while a decrease may indicate declining market expectations for the asset.
Detailed definition
This metric reflects the estimated fair market value of intangible assets associated with a specific product line, such...
Peer comparison
Comparable to fair value disclosures for acquired intangible assets in M&A-heavy pharmaceutical firms.
Metric ID:
amgn_segment_otezla_finite_lived_intangible_assets_fair_value_disclosureHistorical Data
2 periods
| Q1 '25 | Q4 '25 | |
|---|---|---|
| Value | $4.00B | $3.00B |
| QoQ Change | — | -25.0% |
Range$3.00B – $4.00B
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's otezla — finite-lived intangible assets, fair value disclosure?
- Amgen (AMGN) reported otezla — finite-lived intangible assets, fair value disclosure of $3.00B in Q4 2025.
- What does otezla — finite-lived intangible assets, fair value disclosure mean?
- The estimated current market value of the intellectual property and rights associated with a specific drug.